Center for Cardiovascular Disease Prevention and the Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
JAMA. 2010 Feb 17;303(7):631-7. doi: 10.1001/jama.2010.119.
While multiple genetic markers associated with cardiovascular disease have been identified by genome-wide association studies, their aggregate effect on risk beyond traditional factors is uncertain, particularly among women.
To test the predictive ability of a literature-based genetic risk score for cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort of 19,313 initially healthy white women in the Women's Genome Health Study followed up over a median of 12.3 years (interquartile range, 11.6-12.8 years). Genetic risk scores were constructed from the National Human Genome Research Institute's catalog of genome-wide association study results published between 2005 and June 2009.
Incident myocardial infarction, stroke, arterial revascularization, and cardiovascular death.
A total of 101 single nucleotide polymorphisms reported to be associated with cardiovascular disease or at least 1 intermediate cardiovascular disease phenotype at a published P value of less than 10(-7) were identified and risk alleles were added to create a genetic risk score. During follow-up, 777 cardiovascular disease events occurred (199 myocardial infarctions, 203 strokes, 63 cardiovascular deaths, 312 revascularizations). After adjustment for age, the genetic risk score had a hazard ratio (HR) for cardiovascular disease of 1.02 per risk allele (95% confidence interval [CI], 1.00-1.03/risk allele; P = .006). This corresponds to an absolute cardiovascular disease risk of 3% over 10 years in the lowest tertile of genetic risk (73-99 risk alleles) and 3.7% in the highest tertile (106-125 risk alleles). However, after adjustment for traditional factors, the genetic risk score did not improve discrimination or reclassification (change in c index from Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [ATP III] risk score, 0; net reclassification improvement, 0.5%; [P = .24]). The genetic risk score was not associated with cardiovascular disease risk (ATP III-adjusted HR/allele, 1.00; 95% CI, 0.99-1.01). In contrast, self-reported family history remained significantly associated with cardiovascular disease in multivariable models.
After adjustment for traditional cardiovascular risk factors, a genetic risk score comprising 101 single nucleotide polymorphisms was not significantly associated with the incidence of total cardiovascular disease.
尽管全基因组关联研究已经确定了多个与心血管疾病相关的遗传标志物,但它们对风险的综合影响超出了传统因素,这在女性中尤其不确定。
测试基于文献的心血管疾病遗传风险评分的预测能力。
设计、设置和参与者:在女性基因组健康研究中,对 19313 名最初健康的白人女性进行前瞻性队列研究,中位随访时间为 12.3 年(四分位距,11.6-12.8 年)。遗传风险评分是根据 2005 年至 2009 年 6 月发表的国家人类基因组研究所全基因组关联研究结果目录构建的。
心肌梗死、卒中等心血管疾病事件的发生。
共确定了 101 个单核苷酸多态性,这些多态性与心血管疾病或至少 1 个中间心血管疾病表型相关,其在已发表的 P 值<10(-7)下具有统计学意义,并添加风险等位基因以创建遗传风险评分。在随访期间,发生了 777 例心血管疾病事件(199 例心肌梗死、203 例卒中等)。在调整年龄后,遗传风险评分的心血管疾病风险比(HR)为每风险等位基因 1.02(95%置信区间[CI],1.00-1.03/风险等位基因;P =.006)。这相当于在遗传风险最低三分位(73-99 个风险等位基因)的患者中,10 年内的绝对心血管疾病风险为 3%,而在最高三分位(106-125 个风险等位基因)的患者中为 3.7%。然而,在调整传统因素后,遗传风险评分并不能提高区分度或重新分类(专家小组检测、评估和治疗成人高胆固醇血症 [ATP III] 风险评分的变化,0;净重新分类改善,0.5%;P =.24)。遗传风险评分与心血管疾病风险无关(ATP III 调整的 HR/等位基因,1.00;95%CI,0.99-1.01)。相比之下,多变量模型中自我报告的家族史与心血管疾病仍显著相关。
在调整传统心血管危险因素后,由 101 个单核苷酸多态性组成的遗传风险评分与总心血管疾病的发生率无显著相关性。